Baclofen - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for baclofen and what is the scope of patent protection?
Baclofen
is the generic ingredient in eight branded drugs marketed by Amneal, Heritage, Maia Pharms Inc, Mylan Labs Ltd, Rubicon, Piramal Critical, Metacel Pharms Llc, Ani Pharms, Azurity, Ucb Inc, Andas 5 Holding, Appco, Aurobindo Pharma Ltd, Beximco Pharms Usa, Endo Operations, Eywa, Graviti Pharms, Impax, Ivax Sub Teva Pharms, Lannett Co Inc, Mankind Pharma, Micro Labs, Northstar Hlthcare, Norvium Bioscience, Oxford Pharms, Rising, Sun Pharm Inds Inc, Teva, Unichem, Upsher Smith Labs, Usl Pharma, Watson Labs, Zydus Lifesciences, and Novartis, and is included in forty-eight NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Baclofen has fourteen patent family members in eight countries.
There are twenty-one drug master file entries for baclofen. Sixty-five suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for baclofen
International Patents: | 14 |
US Patents: | 8 |
Tradenames: | 8 |
Applicants: | 34 |
NDAs: | 48 |
Drug Master File Entries: | 21 |
Finished Product Suppliers / Packagers: | 65 |
Raw Ingredient (Bulk) Api Vendors: | 149 |
Clinical Trials: | 126 |
Patent Applications: | 6,925 |
Drug Prices: | Drug price trends for baclofen |
Drug Sales Revenues: | Drug sales revenues for baclofen |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for baclofen |
What excipients (inactive ingredients) are in baclofen? | baclofen excipients list |
DailyMed Link: | baclofen at DailyMed |
Recent Clinical Trials for baclofen
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospices Civils de Lyon | Phase 2/Phase 3 |
University of Louisville | Phase 2 |
Institute of Liver and Biliary Sciences, India | N/A |
Generic filers with tentative approvals for BACLOFEN
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | 5MG/5ML | SOLUTION;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for baclofen
Drug Class | gamma-Aminobutyric Acid-ergic Agonist |
Mechanism of Action | GABA A Agonists GABA B Agonists |
Medical Subject Heading (MeSH) Categories for baclofen
Anatomical Therapeutic Chemical (ATC) Classes for baclofen
US Patents and Regulatory Information for baclofen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Usl Pharma | BACLOFEN | baclofen | TABLET;ORAL | 071260-001 | May 6, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Zydus Lifesciences | BACLOFEN | baclofen | TABLET;ORAL | 211659-003 | Apr 17, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Impax | BACLOFEN | baclofen | TABLET;ORAL | 077971-002 | Oct 26, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Mylan Labs Ltd | BACLOFEN | baclofen | INJECTABLE;INTRATHECAL | 209592-002 | Mar 21, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma Ltd | BACLOFEN | baclofen | TABLET;ORAL | 214099-002 | Jul 13, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Amneal | LYVISPAH | baclofen | GRANULES;ORAL | 215422-002 | Nov 22, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Zydus Lifesciences | BACLOFEN | baclofen | TABLET;ORAL | 211659-001 | Nov 23, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for baclofen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-001 | Oct 30, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-002 | Oct 30, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | LIORESAL | baclofen | TABLET;ORAL | 017851-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | LIORESAL | baclofen | TABLET;ORAL | 017851-003 | Jan 20, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-002 | Oct 30, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Ucb Inc | KEMSTRO | baclofen | TABLET, ORALLY DISINTEGRATING;ORAL | 021589-001 | Oct 30, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for baclofen
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 109922801 | 甲硝唑和巴氯芬的混悬剂和稀释剂 (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) | ⤷ Sign Up |
Canada | 3036356 | SUSPENSIONS ET DILUANTS POUR LE METRONIDAZOLE ET LE BACLOFENE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) | ⤷ Sign Up |
European Patent Office | 3509592 | SUSPENSIONS ET DILUANTS POUR LE MÉTRONIDAZOLE ET LE BACLOFÈNE (SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN) | ⤷ Sign Up |
Australia | 2020323846 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2021021277 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2018049184 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2023055457 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.